Arsenal Bio
Arsenal Bio is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Arsenal Bio is a technology company.
ArsenalBio is a clinical-stage biotechnology company developing programmable cell therapies, primarily advanced CAR T-cell treatments for solid tumors like gynecologic cancers.[1][4][5] It engineers CRISPR-edited T cells with multiplex gene modifications, synthetic circuits, genome-scale screening, computational design, and machine learning to enhance persistence, trafficking, tumor targeting, and killing efficacy, addressing limitations of therapies successful in blood cancers.[1][2][3] The company serves cancer patients and the healthcare sector through autologous CAR-T candidates, backed by $630 million in funding including a $325 million Series C, with collaborations like Bristol Myers Squibb licensing its AB-4000 series and partnerships with the Parker Institute for Cancer Immunotherapy.[1][5] Despite growth via deals and trials, it faced a 50% staff layoff in September 2025, signaling cost pressures amid clinical advancement.[2]
ArsenalBio was founded in 2018 or 2019—sources vary slightly—and is headquartered in South San Francisco, California.[1][2][5] Led by Chairman and CEO Ken Drazan, M.D., the leadership includes CTO Tarjei Mikkelsen and CSO Jane Grogan, drawing on expertise in multi-disciplinary science, clinical development, and manufacturing.[1][2][4] The idea emerged from integrating cutting-edge technologies like CRISPR genome engineering, high-throughput target identification, synthetic biology, and machine learning to pioneer programmable immune cell therapies, evolving from early focus on cancer to clinical-stage programs in solid tumors.[2][3][5] Pivotal early traction included a 2020 multi-program deal with Bristol Myers Squibb, yielding the AB-4000 milestone in 2025, and rapid funding scaling to $630 million.[1][5]
ArsenalBio rides the cell therapy revolution, extending CAR-T success from liquid tumors (e.g., lymphoma) to intractable solid tumors, a market gap where ~90% of cancers reside amid rising immunotherapy demand.[1][4] Timing aligns with CRISPR maturation, AI in biology, and post-2020 funding boom in synthetics, fueled by big pharma interest—evident in its BMS deal and $325 million Series C.[1][5] Favorable forces include regulatory nods for cell therapies, manufacturing scale-up, and computational biology's cost reductions, positioning ArsenalBio to influence ecosystem shifts toward "programmable" medicines that tackle tumor heterogeneity.[2][3] Its platform could democratize access, pressuring incumbents and inspiring hybrid bio-AI models in oncology.
ArsenalBio's path hinges on clinical readouts for lead programs in solid tumors, with BMS collaboration potentially yielding first data in 2026-2027, validating its platform amid workforce cuts signaling disciplined burn.[1][2] Trends like AI-accelerated discovery, multi-antigen targeting, and off-the-shelf cells will shape it, possibly enabling IPO or acquisition if Phase 2/3 efficacy hits in gynecologic or other solids.[3][5] Influence may grow via ecosystem partnerships, evolving from pioneer to scale-player if it cracks solid tumor barriers—reinforcing its mission to engineer hope against cancer's complexity.[4]